Pharmaceutical Market Leader Sinopharm Successfully Upgrades Its Supply Chain With Manhattan Associates

Pharmaceutical Market Leader Sinopharm Successfully Upgrades Its Supply Chain With Manhattan Associates
SHANGHAI, China and ATLANTA, Sep 19, 2011 (GlobeNewswire via COMTEX) -- Sinopharm Group's distribution center (DC) in Hunan, China has successfully upgraded its supply chain technology platform with the latest version of Manhattan Associates' /quotes/zigman/67401 MANH -0.55% Warehouse Management solution (WMS). Sinopharm expects Manhattan's WMS will play a vital supporting role in helping the company achieve its target of RMB 10 billion (US$1.6 billion) in revenue in the next five years.

As China's largest pharmaceuticals distributor -- the third largest globally -- Sinopharm has business operations serving the whole of China, and has invested nearly RMB 200 million (US$31 million) in its Hunan distribution center, which opened in May this year. Since implementing Manhattan Associates' WMS, Sinopharm is now able to categorize products and manage storage requirements to meet different manufacturers' needs, which is helping make order picking more efficient and optimizing operating flow. It also has the ability to analyze the performance of the warehouse and can identify areas where productivity and service level improvements can be made. Sinopharm estimates the enhanced capabilities offered by the new system will deliver productivity improvements of up to 30 percent.

The WMS upgrade will also enable the company to manage the increasing volume of stock it is handling, reduce overall distribution costs for manufacturing customers, and provide them with timely, accurate and high-quality distribution services. In addition, Sinopharm is benefiting from the software's reliable tracking and traceability capabilities, enabling the distributor to assist the government departments it currently works with in regulating the pharmaceutical industry, and assuring safe drug use.

"One of our biggest challenges was ensuring our distribution infrastructure could keep up with the pace of growth of the business," said Yang Kaiwen, general manager of Sinopharm Group. "We needed a system that could support rapid volume expansion at the same time as facilitating operational efficiency improvements and allowing us to keep up with the industry's changing regulations. With the implementation of Manhattan's latest warehouse management system, we have been able to achieve our supply chain optimization and industry compliance objectives whilst maintaining our position as market leader."

Receive up-to-date product, customer and partner news directly from Manhattan Associates on Twitter and Facebook.

About Manhattan Associates, Inc.

Manhattan Associates continues to deliver on its 21-year heritage of providing global supply chain excellence to more than 1,200 customers worldwide that consider supply chain optimization core to their strategic market leadership. The company's supply chain innovations include: Manhattan SCOPE(R) a portfolio of software solutions and technology that leverages a Supply Chain Process Platform to help organisations optimize their supply chains from planning through execution; Manhattan SCALE(TM), a portfolio of distribution management and transportation management solutions built on Microsoft .NET technology; and Manhattan Carrier(TM), a suite of supply chain solutions specifically addressing the needs of the motor carrier industry. For more information, please visit www.manh.com .

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Manhattan Associates

 

        CONTACT: Emma Jenkins
        LEWIS - Global Public Relations
        Tel: +852 3944 5000
        [email protected]
        Vivien Wang
        Manhattan Associates
        Tel: +86 6057 3500
        [email protected]
       

 

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.